Reprogramming RNA to transform patients’ lives.

Remix Therapeutics is advancing a new class of therapeutics by modulating RNA processing with small molecules.

Current Beat

Nov | 19 | 2026
Press Release
Remix Therapeutics™ Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
Late-breaking presentation highlights durable clinical activity, including 57% overall response rate at recommended Phase 2 dose in biomarker-positive patients Time on REM-422 treatment reached up to two years and remains ongoing, supporting potential for long term dosing Watertown, Mass., November 19, 2026 – Remix Therapeutics, Inc., a clinical-stage biotechnology company developing small molecule therapies to […]
Jun | 24 | 2026
Press Release
Passage Bio and Remix Therapeutics™ Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers Concurrent oversubscribed $100 million private placement […]
Mar | 19 | 2026
Press Release
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor Adenoid Cystic Carcinoma   WATERTOWN, Mass., March 19, 2026 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing […]

REMaster™ Drug
Discovery Platform

Our proprietary platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease drivers.

mRNA Degrader
REM-422

REM-422 is an investigational first-in-class orally available, small molecule mRNA degrader that targets the pre-mRNA of MYB, a previously undruggable transcription factor known to drive a diverse range of diseases.

It's Sound Science

Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.

Contact

General Inquiry